China Blood Screening Market to 2032
Overview
The China Blood Screening Market is expected to reach a 259.67 USD Million by 2032 and is projected to grow at a CAGR of 14.68% from 2025 to 2032.
Revenue, 2024 (USD Million)
111.00
Forecast, 2032 (USD Million)
259.67
CAGR, 2024 - 2032
14.68%
Report Coverage
China
China Blood Screening Market 2018-2032 USD Million
China Blood Screening Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 111.00 USD Million
- Projected Market Size (2032): 259.67 USD Million
- CAGR (2025-2032): 14.68%
Key Findings of China Blood Screening Market
- The China Blood Screening Market was valued at 111.00 USD Million in 2024.
- The China Blood Screening Market is likely to grow at a CAGR of 14.68% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Reagents & Kits in Products & Services Segment accounted for the largest share of the market with a revenue of 54.71 USD Million
- The fastest growing segment Diagnostic Centers in End User Segment grew Fastest with a CAGR of 15.86% during the forecast period from 2024 to 2032.
China Blood Screening Market Scope
China Blood Screening Market Segmentation & Scope
Technology
- Others
- Western Blot Assay
- Nucleic Acid Test
- Next-Generation Sequencing (NGS)
- Rapid Tests
- Enzyme-Linked Immunosorbent Assay (ELISA)
Disease Type
- Others
- HIV/AIDS
- Respiratory Diseases
- Infectious Diseases
- Cholesterol
- Cold & Flu
- Diabetes Mellitus
- Oncology
Products & Services
- Software & Services
- Instruments
- Reagents & Kits
End User
- Ambulatory Surgical Centers
- Clinics
- Hospitals
- Blood Bank
- Diagnostic Centers
China Blood Screening Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2022 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 111.00 USD Million |
| Market Value in 2032 | 259.67 USD Million |
| CAGR (2025-2032) | 14.68% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Technology,Disease Type,Products & Services,End User |
Regional Insights:
-
Leading Market (2024-2032): China, leading in terms of revenue 111.00 USD Million in 2024
- Key Country: China, leading in terms of revenue with value of 111.00 USD Million in 2024.
Segments and Scope
-
China Blood Screening Market to 2032, By Technology
- Enzyme-Linked Immunosorbent Assay (ELISA) is the largest segment in China Blood Screening Market to 2032 with a revenue of 32.73 USD Million in the year 2024.
- Next-Generation Sequencing (NGS) is the Fastest growing segment in China Blood Screening Market to 2032 with a Growth rate of 14.80 % in forecast period 2025-2032.
-
China Blood Screening Market to 2032, By Disease Type
- Oncology is the largest segment in China Blood Screening Market to 2032 with a revenue of 28.21 USD Million in the year 2024.
- Oncology is the Fastest growing segment in China Blood Screening Market to 2032 with a Growth rate of 15.60 % in forecast period 2025-2032.
-
China Blood Screening Market to 2032, By Products & Services
- Reagents & Kits is the largest segment in China Blood Screening Market to 2032 with a revenue of 54.71 USD Million in the year 2024.
- Instruments is the Fastest growing segment in China Blood Screening Market to 2032 with a Growth rate of 14.38 % in forecast period 2025-2032.
-
China Blood Screening Market to 2032, By End User
- Diagnostic Centers is the largest segment in China Blood Screening Market to 2032 with a revenue of 33.37 USD Million in the year 2024.
- Diagnostic Centers is the Fastest growing segment in China Blood Screening Market to 2032 with a Growth rate of 15.86 % in forecast period 2025-2032.
China Blood Screening Market Company Share Analysis
| Company Name |
|
||
| INNOVUS PHARMACEUTICALS, INC. | |||
| Pfizer Inc. | |||
| Bayer AG | |||
| Cipla Inc. | |||
| GSK plc. | |||
China Blood Screening Market Geographical Sales Distribution, 2018-2032 USD Million
China Blood Screening Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The China Blood Screening Market is segmented based on Segmentation Technology,Disease Type,Products & Services,End User.
China Blood Screening Market was valued at USD 111.00(Revenue in USD Million) in 2022.
China Blood Screening Market is projected to grow at a CAGR of 14.68% during the forecast period of 2024 to 2032.
The Reagents & Kits segment is expected to dominate the China Blood Screening Market, holding a largest market share of 54.71 USD Million in 2024
China Blood Screening Market Scope
China Blood Screening Market Segmentation & Scope
Technology
- Others
- Western Blot Assay
- Nucleic Acid Test
- Next-Generation Sequencing (NGS)
- Rapid Tests
- Enzyme-Linked Immunosorbent Assay (ELISA)
Disease Type
- Others
- HIV/AIDS
- Respiratory Diseases
- Infectious Diseases
- Cholesterol
- Cold & Flu
- Diabetes Mellitus
- Oncology
Products & Services
- Software & Services
- Instruments
- Reagents & Kits
End User
- Ambulatory Surgical Centers
- Clinics
- Hospitals
- Blood Bank
- Diagnostic Centers
Frequently Asked Questions
The China Blood Screening Market is segmented based on Segmentation Technology,Disease Type,Products & Services,End User.
China Blood Screening Market was valued at USD 111.00(Revenue in USD Million) in 2022.
China Blood Screening Market is projected to grow at a CAGR of 14.68% during the forecast period of 2024 to 2032.
The estimated market value of the China Blood Screening Market for final year is USD 259.67 (USD Million).
China Blood Screening Market Company Profiling
Frequently Asked Questions
The China Blood Screening Market is segmented based on Segmentation Technology,Disease Type,Products & Services,End User.
China Blood Screening Market was valued at USD 111.00(Revenue in USD Million) in 2022.
China Blood Screening Market is projected to grow at a CAGR of 14.68% during the forecast period of 2024 to 2032.
The estimated market value of the China Blood Screening Market for final year is USD 259.67 (USD Million).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.